Aug 2026· Advancement of science· 0 citations· 44 references
Medicine
TL;DR
SerpinA3 functions as an endogenous inhibitor of TGF‐β signaling that restrains cardiac fibroblast activation and fibrotic remodeling and is identified as a promising therapeutic target for HF associated with pathological fibrosis.
Abstract
ABSTRACT Background: Cardiac fibrosis is a central driver of adverse remodeling and heart failure (HF), yet effective antifibrotic therapies remain limited. SerpinA3, a member of the serine protease inhibitor family, has been implicated in cardiovascular disease, but its functional role and underlying mechanisms in cardiac remodeling are poorly defined. Methods and Results: Using a transverse aortic constriction (TAC) model, we observed that SerpinA3K expression was markedly reduced in failing mouse hearts and in circulation. Pharmacological supplementation or genetic augmentation of SerpinA3 markedly attenuated cardiac dysfunction and fibrotic remodeling in response to pressure overload. Single‐cell transcriptomic analyses further demonstrated that SerpinA3 suppresses profibrotic fibroblast programs by promoting a transition from activated and extracellular matrix–producing fibroblasts toward a quiescent, pro‐angiogenesis state. Mechanistically, SerpinA3 binds to the extracellular domain of TGF‐beta receptor type‐1, and disrupts TGF‐β receptor type‐1–TGF‐β receptor type‐2 complex formation, thereby preventing downstream Smad2/3 phosphorylation in cardiac fibroblasts. Conclusions: SerpinA3 functions as an endogenous inhibitor of TGF‐β signaling that restrains cardiac fibroblast activation and fibrotic remodeling. By targeting receptor complex assembly, SerpinA3 provides a selective mechanism to modulate profibrotic signaling. These findings identify SerpinA3 as a promising therapeutic target for HF associated with pathological fibrosis.
BACKGROUND
Accumulation of extracellular matrix (ECM) causes tissue fibrosis that contributes to myocardial dysfunction and heart failure (HF), yet there are no approved anti-fibrotic therapeutics that target it. Inhibitors of BET proteins (BETi) reduced fibrosis in preclinical HF models, and clinical-stage BETi, apabe...
S. Wasiak, D. Gilham, L. Fu et al.· Biomedicine & pharmacotherap...· 0 citations
Cardiac fibrosis is a major pathological feature of several cardiovascular diseases and is characterized by excessive extracellular matrix deposition, leading to ventricular stiffening, impaired cardiac function, and ultimately heart failure. Despite its substantial clinical burden, therapies specifically targeting the...
Darío Cañate Cañate, P. Araos, Samir Bolívar González· Current Issues in Molecular...· 0 citations
Elafibranor mitigates TGF-β1-driven cardiac fibrosis by suppressing fibroblast activation and ECM remodelling while promoting adaptive metabolic, redox, and bioenergetic responses, supporting balanced PPAR-α/δ activation as a potential therapeutic strategy for cardiac fibrosis.
M. Paw, L. Minder, A. Laimbacher et al.· bioRxiv· 0 citations
Through high-throughput screening, this work identified CGS15943 (CGS) as the lead antifibrotic compound and validated its activity in human cardiac fibroblasts, three-dimensional engineered heart tissues, and animal models of HF.
Hao Zhang, Rabindra V. Shivnaraine, Lu Ren et al.· Science· 1 citation